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Infectious BAC cloneInfection with feline herpesvirus-1 (FHV-1) is a major cause of upper respiratory and ocular diseases in
Felidae. We report the ﬁrst complete genomic sequence of FHV-1, as well as the construction and charac-
terization of a bacterial artiﬁcial chromosome (BAC) clone of FHV-1, which contains the entire FHV-1
genome and has the BAC vector inserted at the left end of UL. Complete genomic sequences were derived
from both the FHV-1 BAC clone and puriﬁed virion DNA. The FHV-1 genome is 135,797 bp in size with an
overall G+C content of 45%. A total of 78 open reading frames were predicted, encoding 74 distinct proteins.
The gene arrangement is collinear with that of most sequenced varicelloviruses. The virus regenerated from
the BAC was very similar to the parental C-27 strain in vitro in terms of plaque morphology and growth
characteristics and highly virulent in cats in a preliminary in vivo study.pulation and Animal Health,
ersity, 4125 Beaumont Road,
n Fraser University, Burnaby,
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Feline herpesvirus-1 (FHV-1) is a signiﬁcant viral pathogen of
Felidae, ﬁrst isolated in 1957 by Crandell and Maurer (1958). FHV-1
accounts for approximately 50% of all diagnosed viral upper respi-
ratory infections in cats and is also a signiﬁcant cause of ocular lesions
(Nasisse, 1990). The pathobiology of FHV-1 has been reviewed (Gaskell
et al., 2007; Maggs, 2005; Stiles, 2003). Brieﬂy, following entry via
the oronasal route, FHV-1 replicates extensively in the mucosae of the
upper respiratory tract resulting in high fever, depression, anorexia,
sneezing, conjunctivitis, keratitis, and ocular and nasal discharge. The
acute phase of the disease is followed by lifelong latency, a hallmark
of herpesvirus infections. During the latent stage, viral DNA appears
to persist mainly in sensory ganglia. Different biological stresses, or
administration of corticosteroids, can induce the necessary biochemical
stimuli in latently infected cells that lead to renewed production of
infectious virus, which can travel to the periphery and is a potentialsource of viral transmission. In addition to the primary disease, FHV-1 is
also a contributor to feline chronic rhinosinusitis (Johnson and Maggs,
2005).Despite its highmorbidity andworldwide distribution, currently
available vaccines cannot totally protect cats from ﬁeld virus infection
and, as a consequence, fromﬁeldvirus latency (Gaskell andPovey, 1979;
Tham and Studdert, 1987). In addition, some commercial vaccines
are avirulent when administered subcutaneously, but virulent when
administered oronasally (Kruger et al., 1996; Povey, 1979). Since reac-
tivation of latent FHV-1 is common, vaccinated cats may act as asymp-
tomatic carriers and contribute to the spread of virulent virus (Gaskell
and Povey, 1982).
Our knowledge of FHV-1 at the molecular level is still limited.
FHV-1 is a member of Herpesviridae family, Alphaherpesvirinae sub-
family, genus Varicellovirus (Davison et al., 2009). All FHV-1 isolates
appear to be relatively similar, and belong to one serotype. The FHV-1
genome, mapped by restriction endonuclease digestion techniques,
is approximately 134 kb, and has a typical type D structure similar to
other varicelloviruses (Fig. 1A). The double-stranded DNA genome
consists of two segments of unique sequences, known as unique long
(UL) and unique short (US). The US region is ﬂanked by a pair of iden-
tical but inverted repeat sequences, known as terminal repeat short
(TRS) and inverted repeat short (IRS) (Grail et al., 1991; Rota et al.,
1986). Alphaherpesviruses usually encode 65–80 open reading frames
(ORFs) (Alba et al., 2001). FHV-1 has been shown to contain 23 virion-
associated proteins (Fargeaud et al., 1984). Eight glycoproteins have
previously been identiﬁed and designated as gB, gC, gD, gE, gG, gH, gI,
Fig. 1. Diagrams showing (A) structure of FHV-1 genome, (B) location of the BAC cassette and cellular sequence insertion, (C) the composition of the BAC cassette, and (D) the FHV-1
BAC clone after excision of the BAC cassette. The diagram is not to scale.
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been reviewed by Maeda et al. (1998), although it is clear that much
more work is needed to deﬁne their actual functions and roles in viral
pathogenesis and immunity. In recent years, many herpesvirus
genomes of human and veterinary medical importance have been
completely sequenced and annotated, among them herpes simplex
virus types 1 (HSV-1) (McGeoch et al., 1988) and 2 (HSV-2) (Dolan
et al., 1998), varicella-zoster virus (VZV) (Davison and Scott, 1986),
bovine herpesvirus types 1 (BHV-1) (Schwyzer and Ackermann, 1996)
and5 (BHV-5) (Delhon et al., 2003), equineherpesvirus types 1 (EHV-1)
(Telford et al., 1992) and 4 (EHV-4) (Telford et al., 1998), Marek's dis-
ease virus (MDV) (Lee et al., 2000; Tulman et al., 2000), and pseudo-
rabies virus (PRV) (Klupp et al., 2004). Before this report, only portions
of the FHV-1 genomic sequence were available.
Bacterial artiﬁcial chromosomes (BACs) are single copy F-factor-
based plasmid vectors that can stably hold 300 kb or more of foreign
DNA (Shizuya et al., 1992). BACs have advantages over other vectors
including higher cloning capacity, greater stability in Escherichia coli,
and the efﬁciency of manipulation. Because of these advantages, BACs
have been widely used for cloning of entire herpesvirus genomes, and
the resulting clones have been shown to be infectious. Herpesviruses
that have been cloned as BACs include HSV-1 (Saeki et al., 1998; Stav-
ropoulos and Strathdee, 1998), Epstein–Barr virus (Delecluse et al.,
1998), human cytomegalovirus (Borst et al., 1999; Marchini et al.,
2001; Yu et al., 2002), PRV (Smith and Enquist, 1999), EHV-1 (Hansen
et al., 2006; Rudolph et al., 2002), MDV (Schumacher et al., 2000;
Niikura et al., 2006), canine herpesvirus (Arii et al., 2006; Strive et al.,
2006), and FHV-1 (Costes et al., 2006).
In this report, we present the ﬁrst complete and annotated geno-
mic sequence of FHV-1, as well as a BAC clone that contains the entire
FHV-1 genome and is infectious both in vitro and in vivo.Results
Cloning of the FHV-1 genome as a BAC
The C-27 strain FHV-1 genome was cloned as a BAC. US4, which
encodes gG, was selected as the target site for the BAC cassette inser-
tion because it has been shown to be nonessential for virus growth in
several alphaherpesviruses (Balan et al., 1994; Baranowski et al., 1996)
including FHV-1 (Costes et al., 2006). Analyses later revealed that the
BAC vector was in fact inserted near the genomic terminus at the UL
end, 124 bp upstream from the start codon ofUL56 (Fig. 1). In addition,
an unknown sequence of 2570 bp in size was present immediately
upstream of the BAC vector.
Restriction pattern analysis was used to examine the overall
integrity of the FHV-1 genome in the BAC clone. The SalI digestion
pattern of the BAC clone was very similar to that of the parent strain
(Fig. 2). G and M fragments that contained genomic termini would
have become one fragment when the genome circularized but were
instead resolved as three fragments because of the introduction of
additional SalI sites by the BAC insertion. The ﬁrst two of these frag-
ments, 9445 and 9171 bp in size, form a triple band with the H
fragment. The other fragment was 6384 bp in size. The K fragment has
different sizes among bacterial clones. A clone that had a SalI pattern
representative of most bacterial clones and most similar to that of the
C-27 strain was used for all subsequent studies.
In addition to the restriction pattern analysis, PCR assayswere used
to examine the insertion of the BAC vector. Using primers targeting
different BAC vector components (Table 1), including the enhanced
green ﬂuorescence protein (EGFP) gene (RM0901 and RM0944, or
RM0945 and RM0911), the chloramphenicol resistance gene (RM0955
and RM0956), and the bacterial origin of replication (RM0957 and
Table 1
List of primers used in this study.
Primer Sequence (5′–3′)
BAC construction
RM0872 CGTACGTAGTTATTAATAGTAATCAATTACGG
RM0873 GTCGAC GAGCTCACGCCTTAAGATACATTGATGAG
RM0874 ACGCGTGAATTCCCAGGCGACCCGAC
RM0875 ATTTAAAT CGTACGATAACTTCGTATAATGTATGC
TATACGAAGTTATTATCTCTGGTGATCTTGAAGAG
RM0876 AAGCTT GTCGACATAACTTCGTATAGCATACATTA
TACGAAGTTATTAAACTGATTAAATTTAATTAAAG
RM0877 ACGCGTGAGATAGTTGTACCATAAAATCTG
Sequence veriﬁcation of the transfer plasmid BAC04
RM0898 CAATTTCACACAGGAAACAG
RM0899 ACGGATTTTTAAGCACACCA
RM0900 TATTCGAACCATACAACTATC
RM0903 AAGGCGATTAAGTTGGGTA
RM0904 GTTGGGGTCTTTGCTCAGGG
RM0905 AAGAAGTCGTGCTGCTTCATG
RM0906 GGAGTTGTTACGACATTTTGG
RM0907 TTACTATGGGAACATACGTC
PCR assays
RM0901 ATACGATTGTATGTCAAAATAC
RM0910 AACGGAGTAACCTCGGTGTG
RM0911 AATGCTTAATGAATTACAACAG
RM0944 GCGTTACTATGGGAACATAC
RM0945 ATCAGCCATACCACATTTGTAG
RM0955 ACCAATTCTCATGTTTGACAGC
RM0956 ATCGGCACGTAAGAGGTTCC
RM0957 TGGACAGAACAACCTAATGAAC
RM0958 ATGACAGATCCATGTGAAGTG
RM0959 TAATCACGAGCTCCATCAAGGC
RM0988 ATTACGTTTATTGGACCCGAG
RM0989 TGAGACTTTAATTAAATTTAATCAG
RM1025 ACTTCTTTTCTACTTGCCCTGG
RM1026 TAACCCCAGCTTAAACAGAAC
RM1484 TCAGTTATGAATTGAAGGTAATAATCC
RM1485 CTTGTCTGGACAAAAGGAATCTGC
RM1486 TGACAAGGTGACTCTGATCCCA
RM1487 TTGCTGACAGAGGAGCTTTCCA
RM1493 GGGGTTATCATGCTAGCTGCA
RM1494 TGGAAAGCTCCTCTGTCAGCAA
RM1495 CCTTTTGTCCAGACAAGGAGC
Gap closure by primer walking
RM1023 AATATCACCCCGGTAAACGACAC
RM1024 ACTTCCTGGAATAATGCACATC
RM1027 GTTTTTGTTAATACTTCTGTGGAT
Rm1028 AGTATATATAAACCCTACCTACG
RM1037 ACACCTCTCGCTTCTCCTCTGAC
RM1038 TCAGAGACGAAACTGCTCGCATAG
RM1039 AATAGTTATTTTTATCTCACATGC
RM1040 CCTCCGCGGGTTCTAAAACTTG
RM1041 GAGGACGCGGAGAGTGGATGGTTC
GTS565 CATATTCAAATCTGGCCTAAT
GTS569 AGATTTGAATATTTACTGATGTGA
RM1240 TCCTTATTAGGCCAGATTGAATATG
RM1242 TCTACATATGAATAGTAGATTTGAATATTTACT
RM1243 TATTTACTGATGTGATAACTCGATCC
RM1244 GGGGGAAAAAAATTGAGTTGGAGCTC
RM1245 TGAGTTGGAGCTCAGTCTCCATATACG
RM1246 CATATACGGAGGTGGACAGTGTAG
Restriction sites are underlined; loxP sites are in italic.
Fig. 2. Three bacterial clones of FHV-1 BAC, derived from the only viral clone (lanes 1–3),
and C-27 parent strain genomic DNA (lane 4) were treated overnight with restric-
tion endonuclease SalI at 37 °C. The DNA fragments were resolved and visualized in
a 0.7% agarose gel stained with ethidium bromide. Based on sequence analysis, the
linear FHV-1 C-27 strain genome contains the following SalI fragments. A: 16,123 bp;
B: 14,011 bp;C: 13,648 bp;D: 13,466 bp; E: 11,730 bp; F: 10,121 bp;G: 9559 bp;H: 9119 bp;
I: 8564 bp; J: 6977 bp; K: 6701 bp; L: 4951; M: 3996 bp; N: 2587; O: 1724 bp; P: 769 bp;
Q: 677 bp. The 414-bp R fragment and two 330-bp S fragments are not visible in this picture.
The G andM fragments, which contained genomic termini (marked by diamonds in lane 4),
would have become one fragment when the genome circularized, but were instead resolved
as three fragmentsbecauseof the introductionof additional SalI sitesby theBAC insertion. The
ﬁrst two of these fragments, 9445 and 9171 bp in size (arrows), form a triple band, together
with the H fragment. The third fragment was 6384 bp in size (arrows). The size of the K
fragment was variable among bacterial clones (arrowheads). The positions of the1-kb DNA
ladder fragments are indicated to the left of the ﬁgure.
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the FHV-1 genome (data not shown). However, PCR primers targeted
to the expected junction between the BAC vector and the viral se-
quence (RM0910 and RM0959) failed, and primers RM0988 and
RM0989 ampliﬁed the full length of an intact US4. These results sug-
gested that the BAC was inserted into the FHV-1 genome but not into
US4 as intended.
Sequencing of the FHV-1 genome
Using “454” next generation sequencing technology, complete
genome sequences were generated de novo for both the viral genomic
DNA and BAC clone, and then compared to one another. The sequence
assembly of the BAC clone represented 97.62% of the entire FHV-1
genome with an average read depth of 33×. The assembly of the viral
DNA represented 97.52% of the entire genome with an average read
depth of 25×.
To complete the sequences, gaps were ﬁlled by primer walking,
using both pure viral DNA and BAC DNA as template. Threemajor gaps
were present in both assemblies. Gap no. 1 represents the junction of
UL and IRS, gap no. 2 was located inside both IRS and TRS, and gap no. 3contained the genomic termini, or the junction of TRS and UL when the
genome is circularized. Based on the SalI restriction pattern, the
estimated sizes for gaps 1, 2, and 3 were 1.0 kb, 0.6 kb, and 1.0 kb,
respectively. Attempts to close these gaps by primer walking were
partially successful. Gaps 1 and 3 were completely closed, and the
sequence lengths were as predicted. Gap 2 could not be fully se-
quenced. Primer walking results revealed that this region contains
repetitive units of very high G+C content (77%). Use of additional
sequencing chemistry (i.e., dGTP BigDye Terminator) failed to se-
quence through this gap. The remaining ∼314 bp lacking sequence
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of the gap.
When sequences derived from the viral genome and BAC were
compared to each other, they were completely identical, except for
the insertion of the BAC vector at the left end of UL, an addition of a
2570-bp sequence in the BAC clone, and three aforementioned gaps
whose sequence could only be determined from the BAC clone. A
BLASTN search against the nonredundant nucleotide collection data-
base nr/nt (Altschul et al., 1997) found that the additional sequence,
located at bases no. 498–3067, did not resemble any known herpes-
virus sequence. Overlapping PCRs using primers RM1025, RM1026,
RM1484, RM1485, RM1486, RM1487, RM1493, RM1494, and RM1495
(Table 1) ampliﬁed bases no. 512–2373 from both the BAC clone and
the DNA of uninfected Crandell–Reese feline kidney (CRFK) cells (data
not shown). A BLAST search in the WGS Contigs database of the cat
genome project (http://www.ncbi.nlm.nih.gov/projects/genome/
seq/BlastGen/BlastGen.cgi?pid=10703) revealed that the region
between bases no. 2370 and 3052 was very similar to cat genomic
DNA. Therefore, it is very likely that this sequence is a part of the cat
genome, presumably acquired by the virus during the recombination
process in CRFK cells.
The complete FHV-1 genomic sequencewas compared to all FHV-1
DNA sequences in GenBank that contained at least one complete gene.
The results are presented in Table 2. The DNA sequences were highly
similar across strains. The differences observed were mostly limited
to single bases. It was noted that the copy number of repetitive se-
quences can vary between strains or even within the same strain.
The complete DNA sequences of the FHV-1 genome and the FHV-1
BAC clone were deposited in GenBank under accessions FJ478159 and
GU250525, respectively.
Structure of the FHV-1 genome
The FHV-1 genome is 135,797 bp in length. The overall G+C con-
tent of FHV-1 genome is 45%. The genome consists of a 106,369-bp UL
and an 8424-bp US region, with the former being ﬂanked by anTable 2
Comparison of the complete FHV-1 genomic sequence with sequences available in GenBan
Accession no. Strain or
isolate
Sequence
length (nt)
Encoded genes
With complete cds
D14563 G2620 3038 UL45
GM036023 N/A 10,803 UL45, UL44, UL43, UL42, UL41, U
AX018721 N/A 2956 UL45, UL44
AR018958, I58415 N/A 1007 UL45
D86616 C7301 2337 UL44
AX244515, BD396132 N/A 1602 UL44
AJ006454 B927 5587 UL40, UL39
AJ224971 B927 4848 UL30
S66371 C-27 3340 UL27
S49775 C7301 3240 UL27
AX244511, BD396130 N/A 2829 UL27
GM981119 N/A 2847 UL27
E12463 N/A 1619 UL23
M26660 UCD 1619 UL23
S64566 C7301 3746 UL22
AB112595 00-035 3007 UL17
AF022391 C-27 4918 UL2, UL1, ICP0
DQ452613 Taichung 1 882 UL2
D30766 C7301 6175 ICP0
AY740677 B927 3127 US4
S72415 C-27 6208 US4, US6, US7, US8
D30767 C7301 2317 US6
D42113 G2620 8276 US6, US7, US8, US8.5, US9, US10
AX244521, BD396135 N/A 1122 US6
GM981120 N/A 1125 US6
A37005, AR281844 N/A 6154 US7, US8, US8.5, US9, US10, US1
X98448 B927 1155 US7
X98449 B927 1599 US8inverted 33-bp sequence and the latter being ﬂanked by IRS and TRS
elements of 10,469 bp each.
ORF search, gene content, and gene arrangement
To identify all proteins encoded in the genome, we employed
twomethods. First, ORFs encoding proteins of≥60 amino acids with a
methionine start codonwere evaluated for coding potential by search-
ing for homologs in other alphaherpesviruses. Homology searches
were conducted using BLASTX on the nonredundant protein sequence
database nr (Altschul et al., 1997). Other criteria used included com-
pact gene arrangements on both strands with little gene overlap. To
ﬁndnovel genes in the FHV-1 genomeab initio and as a secondapproach
to verify the annotation, the sequence was submitted to GeneMarkS
(Besemer et al., 2001). GeneMarkS predicted 10 fewer genes, namely
UL3, UL11, UL24, UL26.5, UL43, UL53, US2, US6, US8A, and US9. However,
these genes are consistently present among varicelloviruses (Tables 3
and 4), and they were easily identiﬁed using BLASTX, except for US2.
Despite the low degree of sequence similarity, US2 was also predicted
based on relative position similar to other varicelloviruses.
Table 3 lists all FHV-1 ORFs predicted in the genomic sequence and
summarizes the characteristics of the predicted gene products. The
arrangement of these ORFs in the FHV-1 genome is shown in Fig. 3.
Seventy-eight ORFswere predicted in the FHV-1 genome, encoding 74
different proteins, as genes encoding ICP4, US1, and US10 proteins are
found twice, once in the IRS and once in the TRS, and UL15 consists of
two ORFs. Seventy-two ORFs are present as single copies with 64
located in the UL, 7 located entirely in the US, and 1 that initiates in the
US and ends in the TRS. Three ORFs are located entirely in the repeat
region, each present once in IRS and once in TRS. All ORF start locations
were assumed to be the ﬁrst possible ATG. The name of each protein
was given based on its homology to HSV-1 and VZV genes. The pre-
dicted properties and functions assigned to each predicted gene were
based on RefSeq annotations for other alphaherpesviruses in the data-
base of the National Center for Biotechnology Information. In addition
to the ORFs listed in Table 3, 53 ORFs with a coding capacity of morek.
Sequence
identity (%)
Notes
With incomplete cds
UL46, UL44 99.9
L40 UL46, UL39 99.6
UL46, UL43 99.9
UL46, UL44 99.9
UL45 99.8
— 99.9
UL41, UL38 99.4
UL31, UL29 99.5
UL28 99.5
UL28 99.8
— 99.7
— 99.8
UL24, UL22 99.9
UL24, UL22 100.0
UL23, UL21 100.0
UL16 100.0
UL3 99.4 21-mer repeat: N11 vs 11 copies
— 99.7
— 100.0 20-mer repeat: 20.1 vs 6.1 copies
US3, US6 99.9 16-mer repeat: 3 vs 12 copies
US3, US8.5 99.6 16-mer repeat: 13 vs 12 copies
US4, US7 100.0 16-mer repeat: 7 vs 12 copies
, US1 US4 99.9 16-mer repeat: 9 vs 12 copies
— 100.0
— 99.7
— 99.9
— 99.7
— 100.0
Table 3
Predicted FHV-1 ORFs.
Protein Length
(aa)
aa Identity (%) Predicted function or property
EHV-1 EHV-4 BHV-1 BHV-5 PRV VZV
UL56 203 22.9 23.2 N/A N/A 10.5 19.7 Membrane protein UL56
V1 144 27.0 23.9 N/A N/A N/A 15.3 Membrane protein V1
CIRC 278 32.0 31.7 31.5 31.5 N/A 26.1 Myristylated tegument protein CIRC
UL55 209 47.5 46.0 N/A N/A N/A 33.9 Nuclear protein UL55
UL54 438 40.7 41.8 42.1 42.5 42.1 30.8 Multifunctional expression regulator
UL53 344 44.9 46.1 34.0 33.2 34.3 42.6 Envelope glycoprotein K
UL52 1062 48.1 47.3 40.5 43.0 43.9 39.9 Helicase–primase primase subunit
UL51 242 46.4 46.6 38.7 37.8 41.6 38.6 Tegument protein UL51
UL50 325 38.8 38.8 32.8 34.1 36.7 27.7 Deoxyuridine triphosphatase
UL49.5 95 40.0 41.1 31.5 35.2 35.2 32.2 Envelope glycoprotein N
UL49 345 26.2 26.8 26.7 23.6 27.3 19.9 Tegument protein VP22
UL48 447 54.6 54.4 44.0 43.7 46.6 42.6 Transactivating tegument protein VP16
UL47 858 39.3 38.4 29.5 30.8 31.6 19.5 Tegument protein VP13/14
UL46 720 38.8 38.8 31.0 30.7 28.5 27.9 Tegument protein VP11/12
UL45 193 28.3 28.3 N/A N/A N/A N/A Membrane protein UL45
UL44 534 32.1 30.9 29.0 28.2 20.0 28.3 Envelope glycoprotein C
UL43 415 40.3 39.4 27.3 26.7 22.5 24.1 Envelope protein UL43
UL42 395 38.7 39.8 30.5 28.7 27.5 24.1 DNA polymerase processivity subunit
UL41 453 59.6 59.4 52.4 52.6 56.6 40.8 Tegument host shutoff protein
UL40 331 67.0 66.2 65.6 68.3 70.3 64.4 Ribonucleotide reductase subunit 2
UL39 786 64.8 64.7 57.9 58.5 61.2 52.9 Ribonucleotide reductase subunit 1
UL38 463 50.6 50.9 45.8 44.2 48.2 40.6 Capsid triplex subunit 1
UL37 1027 43.9 43.8 34.0 33.5 37.2 32.2 Tegument protein UL37
UL36 3033 42.5 42.6 33.9 34.2 34.9 32.3 Large tegument protein
UL35 108 46.7 43.9 50.0 49.1 54.0 36.8 Small capsid protein
UL34 271 49.8 48.5 44.4 42.0 44.2 44.1 Nuclear egress membrane protein
UL33 123 46.3 45.0 49.1 49.5 45.0 39.0 DNA packaging protein UL33
UL32 582 54.3 53.8 48.8 49.6 53.4 52.6 DNA packaging protein UL32
UL31 337 63.4 62.5 54.1 52.8 61.0 55.3 Nuclear egress lamina protein
UL30 1205 64.9 65.1 59.0 59.4 62.7 58.7 DNA polymerase catalytic subunit
UL29 1200 66.2 66.2 57.7 57.5 59.9 54.4 Single-stranded DNA-binding protein
UL28 779 57.8 59.0 51.3 51.6 53.8 50.5 DNA packaging terminase subunit 2
UL27 948 58.2 59.1 59.2 59.1 59.4 53.2 Envelope glycoprotein B
V32 130 47.2 43.0 N/A N/A N/A 36.9 Protein V32
UL26.5 294 37.3 36.0 21.4 23.2 16.2 26.0 Capsid scaffold protein
UL26 598 49.1 47.3 39.6 40.0 42.0 34.4 Capsid maturation protease
UL25 623 56.1 55.1 52.0 52.0 49.7 49.2 DNA packaging tegument protein UL25
UL24 260 48.6 50.2 38.1 37.6 55.6 36.2 Nuclear protein UL24
UL23 343 47.4 48.0 37.9 36.9 47.3 35.3 Thymidine kinase
UL22 821 33.8 33.1 30.0 29.5 27.4 29.0 Envelope glycoprotein H
UL21 527 47.5 46.9 35.2 36.3 40.4 39.0 Tegument protein UL21
UL20 229 45.9 43.2 31.6 30.7 26.7 33.2 Envelope protein UL20
UL19 1377 72.8 72.2 65.9 66.3 68.1 60.0 Major capsid protein
UL18 312 64.1 64.1 59.8 61.1 58.8 55.3 Capsid triplex subunit 2
UL17 691 51.2 50.8 41.8 41.4 44.4 37.0 DNA packaging tegument protein UL17
UL16 363 52.1 51.0 44.0 45.3 39.1 37.3 Tegument protein UL16
UL15 734 71.3 71.0 63.6 63.5 61.3 61.3 DNA packaging terminase subunit 1
UL14 322 34.5 35.4 32.5 32.7 42.7 31.6 Tegument protein UL14
UL13 606 49.2 49.0 36.8 36.0 31.9 35.5 Tegument serine/threonine protein kinase
UL12 544 59.9 60.4 41.0 41.2 47.1 37.6 Deoxyribonuclease
UL11 76 36.1 35.6 33.8 34.7 25.4 36.1 Myristylated tegument protein
UL10 422 40.7 40.5 36.7 37.0 39.6 33.2 Envelope glycoprotein M
UL9 860 58.5 58.4 48.8 51.5 49.8 46.5 DNA replication origin-binding helicase
UL8 782 46.0 45.2 36.8 36.5 36.2 36.6 Helicase–primase subunit
UL7 296 46.1 44.9 36.9 38.5 40.4 37.3 Tegument protein UL7
UL6 717 57.9 58.7 50.9 53.5 60.1 48.2 Capsid portal protein
UL5 863 70.7 70.0 64.9 65.0 60.5 66.1 Helicase–primase helicase subunit
UL4 236 43.6 42.9 36.4 37.8 32.4 26.7 Nuclear protein UL4
UL3.5 181 21.9 21.4 18.3 16.3 18.0 22.5 Protein V57
UL3 201 67.7 69.5 54.5 51.0 44.4 43.0 Nuclear protein UL3
UL2 293 49.8 49.8 50.0 48.1 46.2 43.4 Uracil-DNA glycosylase
UL1 147 28.8 28.8 25.4 27.3 24.6 27.1 Envelope glycoprotein L
ICP0 498 23.4 22.0 21.4 20.1 18.9 14.2 Ubiquitin E3 ligase ICP0
ICP4 1398 42.7 43.2 39.6 40.7 40.2 35.4 Transcriptional regulator ICP4
US1 334 54.8 53.4 44.3 43.5 33.5 31.2 Regulatory protein ICP22
US10 213 45.0 44.5 N/A N/A N/A 27.1 Virion protein US10
US2 102 12.7 11.8 10.8 11.8 13.7 N/A Virion protein US2
US3 351 54.4 51.6 41.9 41.0 46.1 38.2 Serine/threonine protein kinase US3
US4 434 36.3 36.3 28.7 28.4 27.0 N/A Envelope glycoprotein G
US6 374 24.9 25.1 30.1 30.2 26.3 N/A Envelope glycoprotein D
US7 384 35.4 36.7 23.6 23.4 22.9 23.3 Envelope glycoprotein I
US8 532 45.9 45.4 30.8 29.8 22.9 25.2 Envelope glycoprotein E
US8A 100 13.0 14.6 N/A N/A N/A N/A Membrane protein US8A
US9 152 30.1 35.2 25.9 26.3 35.8 26.7 Membrane protein US9
US10 213 Virion protein US10
US1 334 Regulatory protein ICP22
ICP4 1398 Transcriptional regulator ICP4
The highest percent identity for each protein is indicated in bold.
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Table 4
Differences in gene composition among sequenced Varicellovirus genomes.
Protein FHV-1 EHV-1 EHV-4 BHV-1 BHV-5 PRV VZV Predicted function or property
UL56 + + + − − + + Membrane protein UL56
V1 + + + − − − + Membrane protein V1
CIRC + + + + + − + Myristylated tegument protein CIRC
UL55 + + + − − − + Nuclear protein UL55
VZV ORF13 − − − − − − + Thymidylate synthase
UL45 + + + − − − − Membrane protein UL45
V32 + + + − − − + Protein V32
V67 − + + + + − + Virion protein V67
US10 + + + − − − + Virion protein US10
US4 + + + + + + − Envelope glycoprotein G
US5 − + + − − − − Envelope glycoprotein J
US6 + + + + + + − Envelope glycoprotein D
US8A + + + − − − − Membrane protein US8A
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and 28 were on the bottom strand. However, searches for cellular
or viral homologs of these ORFs failed to ﬁnd any signiﬁcant match,
and none of these ORFs was considered as strong candidates for new
genes.
Table 3 also lists the amino acid sequence similarity of each pro-
tein to their counterparts in the other sequenced varicelloviruses. All
FHV-1 gene products showed some degree of homology to the gene
products of the other varicelloviruses. Not surprisingly, genes involved
in nucleotidemetabolism, DNA replication, and packagingwere among
themost conserved. Glycoprotein geneswere less conserved, although
gB did show a high degree of similarity to gB of the other varicel-
loviruses. FHV-1 proteins were most similar to homologues of EHV-1
and EHV-4, averaging 49.4% and 49.2% animo acid identity, respec-
tively. Phylogenetic relationships between FHV-1 and other varicello-
viruses were examined using single glycoprotein and concatenated
amino acid sequence alignments (McGeoch et al., 2000). The results
are presented in Fig. 4 and showed that FHV-1 ismost closely related to
EHV-1 and EHV-4.
The arrangement of FHV-1 genes is collinear with VZV, BHV-1,
BHV-5, EHV-1, and EHV-4. The gene content is highly similar to those
of varicelloviruses, especially EHV-1 and -4, with a few exceptions
(Table 4). FHV-1 lacks the homologs of V67 and US5, while both are
present in EHV-1 and -4. V67was found in EHV-1, EHV-4, BHV-1, BHV-
5, and VZV, but it is absent in PRV. US5, encoding gJ, was found only in
EHV-1 and -4. None of the genes identiﬁed was unique to FHV-1.
Polyadenylation signals and splice sites
The PolyADQ program (Tabaska and Zhang, 1999) was used to
search for all potential polyadenylation signals in the FHV-1 genome.
The search found 323 sites; eachwas given a score between 0 and 1. In
the PRV study (Klupp et al., 2004), experimental results were used to
determine a cutoff score. Since there were very few, if any, data for the
mapping of FHV-1 transcripts, every signal was located in the com-
plete genomic sequence initially. Many signals did not associate with
any upstream gene, while very often multiple signals were found for
a given ORF or a set of coterminal transcripts. The polyadenylation
signals for each gene were annotated based on the assumption that
each transcript either ends near the termination codon or is a member
of a 3′-coterminal family. The ones that are closest to the stop codon
and have the highest scores were annotated.
UL15 is made up of two exons and is well conserved among her-
pesviruses. The region between and including the two exons of UL15
were submitted to the Neural Network Splice Site Prediction program
conditioned for human splice site recognition (Reese et al., 1997). The
predicted donor site with the highest score (0.98) located 39 bp up-
stream from the end of the ﬁrst ORF of UL15. The predicted acceptorsite with the highest score (0.99) located between the ORF ofUL17 and
the second ORF of UL15. The spliced mRNA would encode a protein of
734 amino acids.
Origins of replication and tandem repeats
The origins of replication of herpesviruses are characterized by the
presence of an AT-rich palindromic sequence. EHV-1, EHV-4, and PRV
have at least three origins of DNA replication: one copy of OriL found
in UL, between UL21 and UL22, and two copies of OriS found in IRS and
TRS (Klupp et al., 2004; Telford et al., 1992, 1998). In contrast, VZV lacks
anOriL (Davison andScott, 1986). In the FHV-1genome, theOriS palin-
dromewas found in IRS and TRS. However, no sequence that resembles
an OriL was found in the region between UL21 and UL22. Comparison
of the DNA sequences in this region between the BAC clone and wild-
type C-27 strain (data not shown) has ruled out the possibility that a
similar palindrome might have been misassembled or deleted during
cloning.
Using the Tandem Repeats Finder program (Benson, 1999), eight
different types of tandem repeat elements at 16 locations in the FHV-1
genome were identiﬁed (Table 5). One tandem repeat element was
found in UL, one in US, and six in IRS/TRS. Four tandem repeat elements
were located at genomic termini. No ORFs were found inside these
repeats. One repeat is located inside ICP4, and Tandem Repeats Finder
found an imperfect 78-mer repeat in UL44. The two repeat units have a
91% match with each other.
Reconstitution of virus particles from BAC clone and excision of the BAC
vector
Virus particles were reconstituted from the BAC by transfecting
CRFK cells with BAC DNA. The reconstituted virus, with the BAC vector
in its genome, producedﬂuorescent plaques in CRFKmonolayers (data
not shown). To reduce possible effects the BAC vector might have on
viral growth characteristics and virulence, CRFK cells were cotrans-
fected with BAC DNA and pcDNA-Cre. pcDNA-Cre expresses Cre pro-
tein, which speciﬁcally recognizes the loxP sites ﬂanking the BAC
cassette and EGFP gene, excises them, and re-ligates the DNA leaving
a single loxP site (Fig. 1). After plaque puriﬁcation, no ﬂuorescent
plaques were found. The excision of BAC vector was also veriﬁed by
PCR and sequence analysis (data not shown). The BAC-excised FHV-1
BAC clone, FHV1ΔBAC, was used for subsequent in vitro and in vivo
characterizations.
In vitro characterization of FHV1ΔBAC
To deﬁne the in vitro growth characteristics of the BAC-derived
virus, plaquemorphologies andmulti-step growth curves for the C-27
Fig. 3. Predicted FHV-1 gene arrangement.
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strain and FHV1ΔBAC virus are morphologically undistinguishable
from each other. The average size of 100 plaques was determined for
each virus strain. The mean plaque diameter of the FHV1ΔBAC viruswas 101% of the C-27 parent strain and not signiﬁcantly different
(P=0.740).
Multistep growth curves were constructed for both the FHV1ΔBAC
virus and the C-27 parent strain (Fig. 5). At 48 and 72 hours p.i., the
Fig. 4. Phylogenetic analyses based on concatenated amino acid sequence alignment of conserved genes (A) and individual glycoprotein amino acid sequence alignments (B). Trees
were generated using the neighbor-joining method. Bootstrap values (1000 replicates) are given for each branch. Scale bars represent the number of amino acid substitutions per
site.
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Table 5
Tandem repeats within the FHV-1 genome.
Location Repeat unit size (bp) Copy no. Sequence Total length (bp) Note
121–497 17 22.2 tggagtctaggtgtggg 377 UL/gap 3
106,506–106,736 21 11 ggcctaataaggaaggggagg 231 IRS/gap 1
(135,497–135,727) (TRS/gap 3)
106,734–106,949 30 7.2 tctggcggtttgtgggttggcatattcaaa 216 IRS/gap 1
(135,284–135,499) (TRS/gap 3)
106,963–107,066 30 3.5 104 IRS/gap 1
(135,167–135,270) (TRS/gap 3)
110,463–110,501 18 2.2 tggagcgacgctcactga 39 IRS/ICP4
(131,732–131,770) (TRS/ICP4)
111,766–111,877 20 6.1 accttcgctcctcccctcgt 122 IRS/between ICP4 and US1
(130,346–130,467) (TRS/between ICP4 and US1)
112,613–112,814 53 3.8 aggttggaagccatgttgttccggttgcacatctaatctacatgaaagtggga 202 IRS/between ICP4 and US1
(129,419–129,620) (TRS/between ICP4 and US1)
112,851–113,459 26 23.4 gggggatcgagggggggcagagggga 609 IRS/gap 2
(128,774–129,382) (TRS/gap 2)
120,219–120,410 16 12 ggggctgtggggacga 192 US/between US4 and US6
Fig. 5.Multistep growth curve of the parent wild-type strain C-27 (grey) and the BAC-
derived virus (black). The wild-type virus and the FHV1ΔBAC were inoculated on CRFK
monolayers at an m.o.i. of 0.01, and supernatants were collected and titrated at 0, 6, 24,
48, and 72 hours post inoculation (p.i.). Error bars at each data point represent ±1
standard deviation.
Table 6
Cumulative clinical score, virus shedding pattern, and virus neutralizing antibody titers
of SPF cats inoculated with the C-27 parent strain, the FHV1ΔBAC strain, or mock-
inoculated with cell culture medium.
Days p.i. AJJ5 AJC2 AJC3 AJD3
(C-27) (FHV1ΔBAC) (FHV1ΔBAC) (EMEM)
VI VN VI VN VI VN VI VN
0 − b4 − b4 − b4 − b4
3 + ND + ND + ND − ND
6 + ND + ND + ND − ND
9 + ND + ND + ND − ND
14 − 64 − 32 − 32 − b4
21 − 64 − 32 − 64 − b4
Cumulative
clinical
score
22 22 26 0
VI: virus isolation; VN: virus neutralization; ND: not determined.
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parent strain. Analysis of the growth curves by ANOVA indicated that
the differences at 48 hours (P=0.003) and 72 hours p.i. (P=0.013)
were statistically signiﬁcant.
Preliminary in vivo characterization
To investigate possible attenuation resulting from BAC cloning, a
preliminary challenge experiment was carried out using four speciﬁc-
pathogen-free (SPF) cats. Two catswere inoculatedwith the FHV1ΔBAC
virus, one cat with the C-27 strain (positive control) and another cat
was inoculatedwith cell culturemedium(negative control). The results
are summarized in Table 6 and Fig. 6. The negative control cat did
not show any clinical signs throughout the study. The cats inoculated
with the C-27 strain and FHV1ΔBAC virus all developed similar clinical
signs. The cumulative clinical scores of the FHV1ΔBAC-infected cats
and the cat inoculated with the parent strain were comparable. Virus
shedding was detected by virus isolation in the cats inoculated with
the C-27 strain and the FHV1ΔBAC virus on days 3, 6, and 9 p.i. Virus
neutralization tests demonstrated that the positive control cat and
the FHV1ΔBAC virus-infected cats all showed seroconversion on day
14 p.i. The neutralizing antibody titers of the FHV1ΔBAC virus-infected
cats and the cat inoculated with the parent strain were very similar.Discussion
We report here the ﬁrst BAC clone containing the entire C-27 strain
FHV-1 genome that exhibits very high virulence in preliminary in vivo
inoculation experiments. The restriction pattern of this BAC clone was
nearly identical to that of the parent C-27 strain with all exceptions
being related to the insertion of the BAC vector or circularization of
the genome (Fig. 2). The size of the genome, derived from both the
sequence assembly and the restriction pattern analysis, is consistent
with the literature (Rota et al., 1986).
An unexpected 2.7-kb cat DNA was inserted along with the BAC
at the genomic termini. A possible explanation is the fact that her-
pesviruses can acquire parts of host genomes, through an unknown
mechanism, during virus replication (Niikura et al., 2006). The SalI
K fragment, which contains three sets of tandem repeats in the TRS,
has different sizes among bacterial clones (Fig. 2). This is likely due to
changes in the number of repeat units, as seen in different strains of
FHV-1 (Table 2).
The BAC clone-derived FHV-1 virus was characterized in vitro by
observing its plaquemorphology and comparative growth curve anal-
ysis. Plaques produced by the BAC clone-derived virus were identical
in size to those produced by the parent C-27 strain. The comparative
growth curve analysis also showed that the BAC clone-derived virus
can grow to N107 TCID50/ml, which was 0.5–1.0 logs lower than its
parent strain (Fig. 5). Although the BAC vector was excised from the
genome through Cre-loxP recombination, parts of the recombination
arms, as well as the cellular sequence, still remained (Fig. 1D). The
Fig. 6. Durations of clinical signs and virus shedding in cats inoculated with the C-27 parent strain (Cat AJJ5) or the FHV1ΔBAC virus (Cats AJC2 and AJC3). The Gantt chart shows the
time frame during which a speciﬁc clinical sign or virus shedding persisted. The cat number is shown next to its respective bar. A bar is shown only if a clinical sign was observed or
virus shedding occurred.
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inﬂuences on virus growth.
In a limited in vivo study, the BAC clone-derived virus showed very
similar pathogenicity in the infected cats. The delayed onset of clinical
signs and the longer persistence (Fig. 6) could be related to the
slightly slower replication of the BAC-derived virus, as shown in the in
vitro characterization. However, since the number of cats used was
very small, it could also be just a difference in susceptibility between
individuals. Although the number was very small, the fact that both of
the cats developed symptoms similar to the wild-type strain
suggested that the BAC-derived virus is infectious, and its virulence
appears to be similar to that of the parent strain. Moreover, in
previous studies, it was shown that the symptoms induced by FHV-1
in experimentally infected cats are quite consistent (Kruger et al.,
1996; Sussman et al., 1995). The fact that this BAC-derived virus
behaves very similarly to its parent strain both in vitro and in vivo
makes it an excellent starting platform for deﬁning the function of
individual viral genes, especially those mediating the virulence of
FHV-1.
We also present the ﬁrst complete and annotated sequence of the
FHV-1 genome, and a complete overview of the molecular composi-
tion of FHV-1. Before this study, sequencing efforts were focused on
smaller fragments of the genome or individual genes from various
strains. A full list of FHV-1 genes completely sequenced before this
report is included in Table 2. Envelope glycoprotein genes drew the
most interest; 8 out of 11 had been completely sequenced.
The physical structure of the FHV-1 genome was ﬁrst mapped
in 1986 when Rota et al. (1986) reported a SalI restriction map of
the C-27 strain. In 1991, Grail et al. (1991) mapped another strain ofFHV-1, B927. The complete genomic sequence showed that the gene
arrangement in the FHV-1 genome is collinear with that of many vari-
celloviruses, including BHV-1, BHV-5, EHV-1, EHV-4, and VZV. The
shufﬂing of gene blocks found in the PRV genome did not appear in
the FHV-1 genome of this strain.
In conclusion, the FHV-1 BAC clone we report contains the entire
FHV-1 genome, the BAC clone-derived virus grows to slightly lower
titers in vitro compared to the C-27 parent strain, and its plaque mor-
phology is not signiﬁcantly altered. Preliminary indications are that its
in vivo virulence is also similar to that of the C-27 parent strain. Recent
advances in recombineering (recombination-mediated genetic engi-
neering) techniques have made it easier to introduce site-speciﬁc
mutations into a BAC clone (Tischer et al., 2006). In addition, random
libraries of herpesvirus BAC mutants can be generated by the use of
transposon-mediated insertion mutagenesis (Brune et al., 1999).
These characteristics, along with the availability of the complete
genome sequence, will make the BAC clone an excellent starting
platform for future mutagenesis-based functional studies of viral
genes and ultimately for future vaccine development.
Materials and methods
Cells and viruses
CRFK cells (ATCC, Manassas, VA) were cultured in Eagle's mini-
mum essential medium (EMEM) containing 10% fetal bovine serum
(FBS) and 10 μg/ml ciproﬂoxacin. The FHV-1 prototype strain C-27
(ATCC, Manassas, VA) was propagated in the CRFK cells and used
as wild-type virus throughout this study. The puriﬁed FHV-1 virions
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tartrate cushion at 24,000×g for 2 hours at 4 °C.
Plasmids and vectors
The 0.6-kb upstream homologous region, which includes the 3′-
end of US3 gene, the intergenic region of US3 and US4, and the 5′-end
of US4 (gG) gene, was ampliﬁed from puriﬁed FHV-1 genomic DNA by
PCR using the Extended High Fidelity PCR System (Roche Applied
Science, Indianapolis, IN) with the following primers: RM0874, which
contains aMluI site at the 5′-end; and RM0875, which contains a SwaI
site, a BsiWI site, and a loxP site at the 5′-end (Table 1). The PCR pro-
duct was cloned into a pCRII vector (Invitrogen, Carlsbad, CA), result-
ing in pCRII-UgG.
The 1.0-kb downstream homologous region, which includes the
intergenic region of US4 (gG) and US6 (gD), and the 5′-end of US6
(gD) gene, was ampliﬁed from puriﬁed FHV-1 genomic DNA by PCR
using the Extended High Fidelity PCR System with the following
primers: RM0876, which contains a HindIII site, a SalI site, and a loxP
site at the 5′-end; and RM0877, which contains a MluI site at the 5′-
end (Table 1). The PCR product was also cloned into a pCRII vector,
resulting in pCRII-DgG.
pCRII-EGFPm2 was constructed as follows. The vector pEGFP-N1
(Clontech Laboratories, Mountain View, CA) was digested by XhoI and
SalI and re-ligated, eliminating XhoI, SacI, HindIII, and SalI sites. The
1.6-kb region containing themodiﬁed EGFP expression cassette,which
includes the CMV immediate early promoter, the EGFP ORF, and SV40
early mRNA polyadenylation signal, was ampliﬁed from the modi-
ﬁed pEGFP-N1 by PCR using Extended High Fidelity PCR System with
the following primers: RM0872, which contains a BsiWI site at the
5′-end, and RM0873, which contains a SacI and SalI site at the 5′-end
(Table 1). The PCR product was cloned into a pCRII vector, resulting
in pCRII-EGFPm2.
pGEM3Zf-DUgG2, which contains two homologous regions and
two loxP sites, was constructed by ligation of the following fragments:
the MluI–SwaI fragment of pCRII-UgG, the HindIII–MluI fragment of
pCRII-DgG, and the pGEM-3Zf vector (Promega, Madison, WI), digested
with HindIII and SmaI.
pGEM3Zf-DUgGEGFP2, which contains two homologous regions,
two loxP sites, and an EGFP expression cassette, was constructed as
follows: pCRII-EGFPm2was digestedwith BsiWIand SacI, and the frag-
ment containing EGFP expression cassette was ligated with pGEM3Zf-
DUgG2, also digested with BsiWI and SacI.
To target the BAC cassette insertion site to US4, the BAC vector
pBAC04, which contains the BAC cassette, two (upstream and down-
stream) homologous recombination arms between two loxP sites and
an EGFP expression cassette, was constructed as follows. The BAC
vector pBeloBAC11 (Invitrogen, Carlsbad, CA) was digested with SalI
and dephosphorylated; the 6.4-kb fragment was puriﬁed and ligated
with the SalI fragment of pGEM3Zf-DUgGEGFP2.
To construct pcDNA-Cre, a plasmid that expresses Cre recombi-
nase, the entire ORF of Cre was excised by KpnI and SmaI digestions
from pGIKS-Cre (ATCC, Manassas, VA) and ligated with pcDNA3.1
vector (Invitrogen, Carlsbad, CA), digested with KpnI and EcoRV.
All the plasmid constructs were veriﬁed by both restriction diges-
tion and sequencing. pBAC04 was transformed into the E. coli strain
DH10B (Invitrogen, Carlsbad, CA). All the other constructs were trans-
formed into the E. coli strains TOP10 or DH5α (both from Invitrogen).
The transformants were plated on selective agar that contained 75 μg/
ml ampicillin or 34 μg/ml chloramphenicol.
DNA extraction
Pure viral genomic DNA was prepared as follows: Puriﬁed virions
were incubated in lysis buffer (0.1 M Tris–Cl, pH 8.0, 1 mM EDTA, 1%
SDS) with 50 μg/ml proteinase K at 37 °C. DNA was subsequentlyextracted with phenol–chloroform–isoamylalcohol (25:24:1) and
precipitated with 100% ethanol. Care was used to avoid shearing the
DNA. High-copy number plasmids were extracted using the Plasmid
Mini Kit (Qiagen, Valencia, CA). Small-scale BAC DNA puriﬁcations
were carried out using the alkaline lysis method (Sambrook and
Russell, 2001). Large-scale and high-purity BAC DNA puriﬁcations
were carried out using the Large Construct Kit (Qiagen, Valencia, CA)
following the manufacturer's instructions.
BAC cloning
The strategy used for cloning FHV-1 genome as a BAC exploits
spontaneous homologous recombinations in the transfected CRFK
cells was similar to those used in previous reports (Costes et al.,
2006; Niikura et al., 2006). To reduce possible sequence alterations
during in vitro passage in cell culture, low-passage C-27 strain virus
(P4) was used for BAC cloning. Puriﬁed FHV-1 genomic DNA and
pBAC04 were cotransfected into CRFK cells using Lipofectamine
2000 (Invitrogen, Carlsbad, CA) according to the manufacturer's
instructions. The supernatant of cotransfected cells was collected for
plaque assay, and plaques were examined for EGFP expression. One
virus clone that consistently produced ﬂuorescent plaques was
obtained. After two times of plaque puriﬁcation, CRFK cells were
inoculated with this virus clone, and the circular form replication
intermediate of the virus genome was extracted from the cells using
the method of Hirt (1967) and transformed into E. coli DH10B cells.
Colonies growing on the chloramphenicol plate were examined for
the presence of FHV-1 genome and BAC vector by restriction pattern
analysis and PCR.
Reconstitution of infectious virus from BAC
The CRFK cells were cotransfected with 1 μg of the BAC DNA and
1 μg of pcDNA-Cre using Lipofectamine 2000 (Invitrogen, Carlsbad,
CA) according to the manufacturer's instructions.
Sequencing, sequence assembly, and gap closure
The majority of the sequence was determined by shotgun se-
quencing using the high-throughput pyrosequencing instrument
Genome Sequencer 20 (Roche Applied Science, Indianapolis, IN) at
the Genomics Core of Michigan State University's Research Technol-
ogy Support Facility (RTSF). The reads were assembled using the
Newbler assembly program (Roche Applied Science, Indianapolis, IN)
at the Bioinformatics Core of RTSF. Gaps were closed by primer
walking. Gap closure was carried out using BigDye Terminator 3.0 and
dGTP BigDye Terminator chemistries and Gene Analyzer 3100
(Applied Biosystems, Foster City, CA).
ORF ﬁnding and sequence analysis
To identify the genes encoded in the FHV-1 genome, all potential
ORFs with a minimum length of 60 codons and a methionine as start
codon were analyzed for homology to known proteins using BLASTX
against nonredundant protein database (Altschul et al., 1997). To ﬁnd
novel genes in the FHV-1 genome ab initio, and as a second approach
to verify the annotation, the sequence was submitted to GeneMarkS
(Besemer et al., 2001). To search for polyadenylation signals, the
FHV-1 genome sequence was submitted to PolyADQ, a eukaryotic
polyadenylation signal search engine (Tabaska and Zhang, 1999). The
Neural Network Splice Site Prediction program conditioned for
human splice site recognition (Reese et al., 1997) was used to identify
possible splice donor and acceptor sites of UL15. The Tandem Repeats
Finder program(Benson, 1999)was used to search for tandem repeats.
Phylogenetic analyses were carried out using the MEGA4 software
(Tamura et al., 2007).
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One hundred ﬁfty TCID50 units of the virus was inoculated on
CRFK monolayers. After a 1-hour adsorption, the diluted viruses were
removed, and fresh growth medium was added. The cells were then
incubated at 37 °C in an atmosphere of 5% CO2. After 40 hours of
incubation, 100 plaques produced by each virus were photographed
and the diameters were determined using the QCapture software
(QImaging, Surrey, British Columbia, Canada). The measurements
were analyzed by ANOVA.
Multi-step growth curve
The wild-type virus and the BAC clone were inoculated on CRFK
monolayers in triplicate at an m.o.i. of 0.01. After a 1-hour adsorption,
the diluted viruses were removed, and the cells were overlaid with
fresh medium. The ﬁrst supernatant samples were collected at this
time as 0-hour p.i. The monolayers were then incubated at 37 °C in an
atmosphere of 5% CO2. Supernatants were collected at 0, 6, 24, 48, and
72 hours p.i. and stored at −80 °C until titration. The mean titers of
each time point were analyzed by ANOVA.
Cats
Four 12-week-old female SPF cats were used (Liberty Research,
Waverly, NY). Cats were housed in individual cages in rooms with
controlled temperature, humidity, and lighting. They were fed a com-
bination of dry and moist diets. Each group of cats was housed in a
separate Biocontainment Level-2 room. All cats were acclimated for
13 days before virus exposure. Two cats were inoculated oronasally
with 2×105 TCID50 of the FHV1ΔBAC. The other two cats were either
inoculated oronasally with 2×105 TCID50 of the C-27 strain wild-type
virus (positive control) or cell culture medium (negative control). The
titers were rechecked before inoculation. Clinical signs induced by
inoculation of the viruses were scored as described in the USDA
Supplemental Assay Method 311 (U.S. Department of Agriculture,
Animal and Plant Health Inspection Service, National Animal Veterinary
Services Laboratory, 1985; Table 1). Oral swabs were collected from
each cat at days 0, 3, 6, 9, 14, and 21 p.i. for virus isolation. Serum
samples were collected from each cat at days 0, 14, and 21 p.i. for virus
neutralization testing. The cat study was reviewed and approved by the
Institutional Animal Care and Use Committee at Michigan State
University.
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